Cargando…

Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine

Calcitonin gene-related peptide (CGRP) pathway-targeted treatments have been shown to be efficacious in the prevention of episodic and chronic migraine. Currently approved therapies include monoclonal antibodies (mAbs) that target CGRP (eptinezumab, fremanezumab, and galcanezumab) and the CGRP recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Mackenzie, Kimberly D., Ortega, Mario, Kessler, Yoel, Campos, Verena Ramirez, Krasenbaum, Lynda J., Carr, Karen, Ning, Xiaoping, Stratton, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747098/
https://www.ncbi.nlm.nih.gov/pubmed/36523559
http://dx.doi.org/10.3389/fphys.2022.1067274
_version_ 1784849515799379968
author Mackenzie, Kimberly D.
Ortega, Mario
Kessler, Yoel
Campos, Verena Ramirez
Krasenbaum, Lynda J.
Carr, Karen
Ning, Xiaoping
Stratton, Jennifer
author_facet Mackenzie, Kimberly D.
Ortega, Mario
Kessler, Yoel
Campos, Verena Ramirez
Krasenbaum, Lynda J.
Carr, Karen
Ning, Xiaoping
Stratton, Jennifer
author_sort Mackenzie, Kimberly D.
collection PubMed
description Calcitonin gene-related peptide (CGRP) pathway-targeted treatments have been shown to be efficacious in the prevention of episodic and chronic migraine. Currently approved therapies include monoclonal antibodies (mAbs) that target CGRP (eptinezumab, fremanezumab, and galcanezumab) and the CGRP receptor (erenumab), and small molecule CGRP receptor antagonists (atogepant and rimegepant). While CGRP pathway–targeted treatments are generally well-tolerated, in a review article by Holzer and Holzer-Petsche published in the January 2022 issue of Frontiers in Physiology the authors discussed the role of the CGRP pathway in gastrointestinal physiology, with a specific focus on constipation associated with the use of CGRP pathway–targeted treatments. The authors state that real-world surveys have shown constipation to be a “major adverse event” reported in “more than 50% of patients treated with erenumab, fremanezumab or galcanezumab.” As described in the current commentary, the limited data from the cited references in the review article by Holzer and Holzer-Petsche do not support that statement.
format Online
Article
Text
id pubmed-9747098
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97470982022-12-14 Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine Mackenzie, Kimberly D. Ortega, Mario Kessler, Yoel Campos, Verena Ramirez Krasenbaum, Lynda J. Carr, Karen Ning, Xiaoping Stratton, Jennifer Front Physiol Physiology Calcitonin gene-related peptide (CGRP) pathway-targeted treatments have been shown to be efficacious in the prevention of episodic and chronic migraine. Currently approved therapies include monoclonal antibodies (mAbs) that target CGRP (eptinezumab, fremanezumab, and galcanezumab) and the CGRP receptor (erenumab), and small molecule CGRP receptor antagonists (atogepant and rimegepant). While CGRP pathway–targeted treatments are generally well-tolerated, in a review article by Holzer and Holzer-Petsche published in the January 2022 issue of Frontiers in Physiology the authors discussed the role of the CGRP pathway in gastrointestinal physiology, with a specific focus on constipation associated with the use of CGRP pathway–targeted treatments. The authors state that real-world surveys have shown constipation to be a “major adverse event” reported in “more than 50% of patients treated with erenumab, fremanezumab or galcanezumab.” As described in the current commentary, the limited data from the cited references in the review article by Holzer and Holzer-Petsche do not support that statement. Frontiers Media S.A. 2022-11-29 /pmc/articles/PMC9747098/ /pubmed/36523559 http://dx.doi.org/10.3389/fphys.2022.1067274 Text en Copyright © 2022 Mackenzie, Ortega, Kessler, Campos, Krasenbaum, Carr, Ning and Stratton. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Mackenzie, Kimberly D.
Ortega, Mario
Kessler, Yoel
Campos, Verena Ramirez
Krasenbaum, Lynda J.
Carr, Karen
Ning, Xiaoping
Stratton, Jennifer
Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
title Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
title_full Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
title_fullStr Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
title_full_unstemmed Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
title_short Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
title_sort commentary: constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747098/
https://www.ncbi.nlm.nih.gov/pubmed/36523559
http://dx.doi.org/10.3389/fphys.2022.1067274
work_keys_str_mv AT mackenziekimberlyd commentaryconstipationcausedbyanticalcitoningenerelatedpeptidemigrainetherapeuticsexplainedbyantagonismofcalcitoningenerelatedpeptidesmotorstimulatingandprosecretoryfunctionintheintestine
AT ortegamario commentaryconstipationcausedbyanticalcitoningenerelatedpeptidemigrainetherapeuticsexplainedbyantagonismofcalcitoningenerelatedpeptidesmotorstimulatingandprosecretoryfunctionintheintestine
AT kessleryoel commentaryconstipationcausedbyanticalcitoningenerelatedpeptidemigrainetherapeuticsexplainedbyantagonismofcalcitoningenerelatedpeptidesmotorstimulatingandprosecretoryfunctionintheintestine
AT camposverenaramirez commentaryconstipationcausedbyanticalcitoningenerelatedpeptidemigrainetherapeuticsexplainedbyantagonismofcalcitoningenerelatedpeptidesmotorstimulatingandprosecretoryfunctionintheintestine
AT krasenbaumlyndaj commentaryconstipationcausedbyanticalcitoningenerelatedpeptidemigrainetherapeuticsexplainedbyantagonismofcalcitoningenerelatedpeptidesmotorstimulatingandprosecretoryfunctionintheintestine
AT carrkaren commentaryconstipationcausedbyanticalcitoningenerelatedpeptidemigrainetherapeuticsexplainedbyantagonismofcalcitoningenerelatedpeptidesmotorstimulatingandprosecretoryfunctionintheintestine
AT ningxiaoping commentaryconstipationcausedbyanticalcitoningenerelatedpeptidemigrainetherapeuticsexplainedbyantagonismofcalcitoningenerelatedpeptidesmotorstimulatingandprosecretoryfunctionintheintestine
AT strattonjennifer commentaryconstipationcausedbyanticalcitoningenerelatedpeptidemigrainetherapeuticsexplainedbyantagonismofcalcitoningenerelatedpeptidesmotorstimulatingandprosecretoryfunctionintheintestine